Circumvention of tumor cell escape following specific immunotherapy

Cancer Biotherapy and Radiopharmaceuticals

Volumn 15, Issue 2, 2000, Pages 141-152

  Frost, Patrick ^a   Bonavida, Benjamin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chemotherapy; CTL; FasR FasL; Immunotherapy; MART 1; Perforin

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FAS LIGAND; GAMMA INTERFERON; MELANOMA ANTIGEN; NITRIC OXIDE; PERFORIN; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR;

ANIMAL MODEL; ANTIGEN EXPRESSION; APOPTOSIS; CANCER IMMUNOTHERAPY; CROSS RESISTANCE; CYTOTOXIC T LYMPHOCYTE; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SENSITIZATION; TUMOR CELL;

EID: 0034109218     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2000.15.141     Document Type: Review

References (107)

1. Wood AC, Elvin P, Hickman JA. Induction of apoptosis by anti-cancer drugs with disparate modes of action: kinetics of cell death and changes in c-myc expression. Br J Cancer 1995;71:937-41.
2. Bonavida B, Safrit J, Morimoto H, Mizutani Y, Uslu R, Borsellino N, Frost P, Berek J, Belldegrun A, Zighelboim J, Ng CP, Mori S. Cross-resistance of tumor cells to chemotherapy and immunotherapy: approaches to revers resistance and implications in gene therapy (Review). Oncology Reports 1997;4:201-205.
3. Frost P, Ng CP, Belldegrun A, Bonavida B. Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity. Cell Immunol 1997;180:70-83.
4. Uslu R, Borsellino N, Frost P, Garban H, Ng CP, Mizutani Y, Belldegrun A, Bonavida B. Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis. Clin Cancer Res 1997;3:963-72.
5. Safrit JT, Bonavida B. Sensitivity of resistant human tumor cell lines to tumor necrosis factor and adriamycin used in combination: correlation between down-regulation of tumor necrosis factor-messenger RNA induction and overcoming resistance. Cancer Res 1992;52:6630-7.
6. Morimoto H, Yonehara S, Bonavida B. Overcoming tumor necrosis factor and drug resistance of human tumor cell lines by combination treatment with anti-Fas antibody and drugs or toxins. Cancer Res 1993;53:2591-6.
7. Mizutani Y, Bonavida B, Nio Y, Yoshida O. Overcoming TNF-alpha and drug resistance of human renal cell carcinoma cells by treatment with pentoxifylline in combination with TNF-alpha or drugs: the role of TNF-alpha mRNA downregulation in tumor cell sensitization. J Urol 1994;151:1697-702.
8. Mori S, Murakami-Mori K, Nakamura S, Ashkenazi A, Bonavida B. Sensitization of AIDS-Kaposi's sarcoma cells to Apo-2 ligand-mduced apoptosis by actinomycin D. J Immunol 1999;162:5616-23.
9. Mizutani Y, Bonavida B, Nio Y, Yoshida O. Enhanced susceptibility of cis-diamminedichloroplatinum-treated K562 cells to lysis by peripheral blood lymphocytes and lymphokine activated killer cells. Cancer 1993;71:1313-21.
10. Safrit JT, Berek JS, Bonavida B. Sensitivity of drug-resistant human ovarian tumor cell lines to combined effects of tumor necrosis factor (TNF-alpha) and doxorubicin: failure of the combination to modulate the MDR phenotype. Gynecol Oncol 1993;48:214-20.
11. Nio Y, Zighelboim J, Berek JS, Bonavida B. Augmentation of cytotoxicity of lymphokine activated killer cells on ovarian tumor cells by various biological response modifiers. Anticancer Res 1990;10: 441-6.
12. Uslu R, Jewett A, Bonavida B. Sensitization of human ovarian tumor cells by subtoxic CDDP to anti-fas antibody-mediated cytotoxicity and apoptosis. Gynecol Oncol 1996;62:282-91.
13. Garban HJ, Bonavida B. Nitric oxide sensitizes ovarian tumor cells to Fas-induced apoptosis. Gynecol Oncol 1999;73:257-64.
14. Mizutani Y, Yoshida O, Bonavida B. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatmum (II). J Urol 1998;160:561-70.
15. Bonavida B, Ng C-P, Jazirehi A, Schiller G, Mizutani Y. Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: The trail to non-toxic cancer therapeutics (review). International Journal of Oncology 1999; 15:793-802.
16. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor- infiltrating lymphocytes. Science 1986;233:1318-21.
17. Marincola FM, Da Pozzo LF, Drucker BJ, Holder WD Jr. Adoptive immunotherapy of human pancreatic cancer with lymphokine-activated killer cells and interleukin-2 in a nude mouse model. Surgery 1990;108:919-29.
18. Hewitt HB. The choice of animal tumors for experimental studies of cancer therapy. Adv Cancer Res 1978;27:149-200.
19. Chang AE, Shu S. Current status of adoptive immunotherapy of cancer. Crit Rev Oncol Hematol 1996;22:213-28.
20. Ribas A, Bui LA, Butterfield LH, Vollmer CM, Jilani SM, Dissette VB, Glaspy JA, McBride WH, Economou JS. Antitumor protection using murine dendritic cells pulsed with acid-eluted peptides from in vivo grown tumors of different immunogenicities [In Process Citation]. Anticancer Res 1999;19:1165-70.
21. Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 1976;193:1007-8.
22. Sano T, Saijo N, Sasaki Y, Shinkai T, Eguchi K, Tamura T, Sakurai M, Takahashi H, Nakano H, Nakagawa K, et al. Three schedules of recombinant human interleukin-2 in the treatment of malignancy: side effects and immunologic effects in relation to serum level. Jpn J Cancer Res 1988;79:131-43.
23. Sondel PM, Kohler PC, Hank JA, Moore KH, Rosenthal NS, Sosman JA, Bechhofer R, Storer B. Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer. Cancer Res 1988;48:2561-7.
24. Siegel JP, Puri RK. Interleukin-2 toxicity. J Clin Oncol 1991;9:694-704.
25. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985;313:1485-92.
26. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987;316:889-97
27. Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, Aebersold P, Leitman S, Linehan WM, Seipp CA, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer [published erratum appears in J Natl Cancer Inst 1993 Jul 7;85(13):1091]. J Natl Cancer Inst 1993;85:622-32.
28. Steger GG, Kaboo R, deKernion JB, Figlin R, Belldegrun A. The effects of granulocyte-macrophage colony-stimulating factor on tumour-infiltrating lymphocytes from renal cell carcinoma. Br J Cancer 1995;72:101-7.
29. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhom JH, White DE. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2 [see comments]. J Natl Cancer Inst 1994;86:1159-66.
30. Whiteside TL, Parmian, G. Tumor-infiltrating lymphocytes: their phenotype, functions and clinical use. Cancer Immunol Immunother 1994;39:15-21.
31. Schiltz PM, Beutel LD, Nayak SK, Dillman RO. Characterization of tumor-infiltrating lymphocytes derived from human tumors for use as adoptive immunotherapy of cancer. J Immunother 1997; 20:377-86.
32. Topalian SL, Solomon D, Rosenberg SA. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 1989;142:3714-25.
33. Dillman RO, Oldham RK, Barth NM, Cohen RJ, Minor DR, Birch R, Yannelli JR, Maleckar JR, Sferruzza A, Arnold J, et al. Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trial. Cancer 1991;68:1-8.
34. Van den Eynde B, Hainaut P, Herin M Knuth A, Lemoine C, Weynants P, van der Bruggen P, Fauchet R, Boon T. Presence on a human melanoma of multiple antigens recognized by autologous CTL. Int J Cancer 1989;44:634-40.
35. Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR, Appella E, Rosenberg SA. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994;180:347-52.
36. Coulie PG, Brichard V, Van Pel A, Wolfel T, Schneider J, Traversari C, Mattei S, De Plaen E, Lurquin C, Szikora JP, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HI A-A2 melanomas [see comments]. J Exp Med 1994;180:35-42.
37. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, Miki T, Rosenberg SA. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A 1994;91:3515-9.
38. Brichard V, Van Pel A, Wolfel T, Wolfel C, De Plaen E, Lethe B, Coulie P, Boon T. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993;178:489-95.
39. Robbins PF, el-Gamil M, Kawakami Y, Stevens E, Yannelli JR, Rosenberg SA. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy [published erratum appears in Cancer Res 1994 Jul 15; 54(14): 3952]. Cancer Res 1994;54:3124-6.
40. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-7.
41. Gaugler B, Van den Eynde B, van der Bruggen P, Romero P, Gaforio JJ, De Plaen E, Lethe B, Brasseur F, Boon T. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994;179:921-30.
42. Cormier JN, Salgaller ML, Prevette T, Barracchini KC, Rivoltini L, Restifo NP, Rosenberg SA, Marincola FM. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A [see comments]. Cancer J Sci Am 1997;3:37-44.
43. Salgaller ML, Marincola FM, Cormier JN, Rosenberg SA. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 1996;56:4749-57.
44. Perez-Diez A, Butterfield LH, Li L, Chakraborty NG, Economou JS, Mukherji B. Generation of CD8+ and CD4+ T-cell response to dendritic cells genetically engineered to express the MART-1/Melan-A gene. Cancer Res 1998;58:5305-9.
45. Butterfield LH, Jilani SM, Chakraborty NG, Bui LA, Ribas A, Dissette VB, Lau R, Gamradt SC, Glaspy JA, McBride WH, Mukherji B, Economou JS. Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. J Immunol 1998;161:5607-13.
46. Butterfield LH, Stoll TC, Lau R, Economou JS. Cloning and analysis of MART-1/Melan-A human melanoma antigen promoter regions. Gene 1997;191:129-34.
47. Dalerba P, Ricci A, Russo V, Rigatti D, Nicotra MR, Mottolese M, Bordignon C, Natali PG, Traversari C. High homogeneity of MAGE, BAGE, GAGE, tyrosinase and Melan-A/MART-1 gene expression in clusters of multiple simultaneous metastases of human melanoma: implications for protocol design of therapeutic antigen-specific vaccination strategies. Int J Cancer 1998;77:200-4.
48. Cormier JN, Hijazi YM, Abati A, Fetsch P, Bettinotti M, Steinberg SM, Rosenberg SA, Marincola FM. Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo. Int J Cancer 1998;75:517-24.
49. Labarriere N, Diez E, Pandolfino MC, Viret C, Guilloux Y, Le Guiner S, Fonteneau JF, Dreno B, Jotereau F. Optimal T cell activation by melanoma cells depends on a minimal level of antigen transcription. J Immunol 1997;158:1238-45.
50. Hudrisier D, Kessler B, Valitutti S, Horvath C, Cerottini JC, Luescher IF. The efficiency of antigen recognition by CD8+ CTL clones is determined by the frequency of serial TCR engagement. J Immunol 1998;161:553-62.
51. Bachmann MF, Ohteki T, Faienza KM, Zakarian A, Kagi D, Speiser DE, Ohashi PS. Altered peptide ligands trigger perforin-rather than Fas-dependent cell lysis. J Immunol 1997;159:4165-70.
52. Wong B, Arron J, Choi Y. T cell receptor signals enhance susceptibility to Fas-mediated apoptosis. J Exp Med 1997;186:1939-44.
53. Jager E, Ringhoffer M, Altmannsberger M, Arand M, Karbach J, Jager D, Oesch F, Knuth A. Immuno-selection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer 1997;71:142-7.
54. Cormier JN, Panelli MC, Hackett JA, Bettinotti MP, Mixon A, Wunderlich J, Parker LL, Restifo NP, Ferrone S, Marincola FM. Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model. Int J Cancer 1999;80:781-90.
55. Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern PL. Natural history of HLA expression during tumour development. Immunol Today 1993;14:491-9.
56. Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995;16:487-94.
57. Marincola FM, Shamamian P, Alexander RB, Gnarra JR, Turetskaya RL, Nedospasov SA, Simonis TB, Taubenberger JK, Yannelli J, Mixon A, et al. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J Immunol 1994;153:1225-37.
58. DeMars R, Rudersdorf R, Chang C, Petersen J, Strandtmann J, Korn N, Sidwell B, Orr HT. Mutations that impair a posttranscriptional step in expression of HLA-A and -B antigens. Proc Natl Acad Sci U S A 1985;82:8183-7.
59. Cromme FV, Airey J, Heemels MT, Ploegh HL, Keating PJ, Stern PL, Meijer CJ, Walboomers JM. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med 1994;179:335-40.
60. Browning M, Petronzelli F, Bicknell D, Krausa P, Rowan A, Tonks S, Murray N, Bodmer J, Bodmer W. Mechanisms of loss of HLA class I expression on colorectal tumor cells. Tissue Antigens 1996;47:364-71.
61. Gervois N, Guilloux Y, Diez E, Jotereau F. Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions. J Exp Med 1996;183:2403-7.
62. Chakraborty NG, Mukherji B. Human melanoma-specific, noncytolytic CD8+ T cells that can synthesize type I cytokine. Cancer Res 1998;58:1363-6.
63. Loftus DJ, Squarcina P, Nielsen MB, Geisler C, Castelli C, Odum N, Appella E, Parmiani G, Rivoltini L. Peptides derived from self-proteins as partial agonists and antagonists of human CD8+ T-cell clones reactive to melanoma/ melanocyte epitope MART1(27-35). Cancer Res 1998;58:2433-9.
64. Jager E, Jager D, Knuth A. Strategies for the development of vaccines to treat breast cancer. Recent Results Cancer Res 1998;152:94-102.
65. Kagi D, Vignaux F, Ledermann B, Burki K, Depraetere V, Nagata S, Hengartner H, Golstein P. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994;265:528-30.
66. Kagi D, Ledermann B, Burki K, Zinkernagel RM, Hengartner H. Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Annu Rev Immunol 1996;14:207-32.
67. Matloubian M, Suresh M, Glass A, Galvan M, Chow K, Whitmire JK, Walsh CM, Clark WR, Ahmed R. A role for perforin in downregulating T-cell responses during chronic viral infection. J Virol 1999; 73:2527-36.
68. Dhein J, Walczak H, Baumler C, Debatin KM, Krammer PH. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95) [see comments]. Nature 1995; 373:438-41.
69. Garner R, Helgason CD, Atkinson EA, Pinkoski MJ, Ostergaard HL, Sorensen O, Fu A, Lapchak PH, Rabinovitch A, McElhaney JE, et al. Characterization of a granule-independent lytic mechanism used by CTL hybridomas. J Immunol 1994;153:5413-21.
70. Griffith TS, Rauch CT, Smolak PJ, Waugh JY, Boiani N, Lynch DH, Smith CA, Goodwin RG, Kubin MZ. Functional analysis of TRAIL receptors using monoclonal antibodies. J Immunol 1999; 162:2597-605.
71. Chen Q, Jackson H, Gibbs P, Davis ID, Trapani J, Cebon J. Spontaneous T cell responses to melanoma differentiation antigens from melanoma patients and healthy subjects. Cancer Immunol Immunother 1998;47:191-7.
72. Jager E, Ringhoffer M, Karbach J, Arand M, Oesch F, Knuth A. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer 1996;66:470-6.
73. Mizutani Y, Bonavida B, Koishihara Y, Akamatsu K, Ohsugi Y, Yoshida O. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Cancer Res 1995;55:590-6.
74. Chmura SJ, Nodzenski E, Beckett MA, Kufe DW, Quintans J, Weichselbaum RR. Loss of ceramide production confers resistance to radiation-induced apoptosis. Cancer Res 1997;57:1270-5.
75. Borsellino N, Belldegrun A, Bonavida B. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res 1995;55:4633-9.
76. Mizutani Y, Bonavida B. Overcoming cis-diamminedichloroplatmum (II) resistance of human ovarian tumor cells by combination treatment with cis-diamminedichloroplatinum (II) and tumor necrosis factor-alpha. Cancer 1993;72:809-18.
77. Mizutani Y, Fukumoto M, Bonavida B, Yoshida O. Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide. Cancer 1994;74:2546-54.
78. Mizutani Y, Bonavida B, Yoshida O. Cytotoxic effect of diphtheria toxin used alone or in combination with other agents on human renal cell carcinoma cell lines. Urol Res 1994;22:261-6.
79. Stein U, Walther W, Shoemaker RH. Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells. J Natl Cancer Inst 1996;88:1383-92.
80. Feliu J, Gonzalez Baron M, Chacon JI, Espinosa E, Garrido P, Castro J, Escobar Y, Colmenarejo A, Jara C, Garcia Giron C, Espinosa J, Ordonez A. Treatment of metastatic malignant melanoma with cisplatin plus tamoxifen. Cancer Chemother Pharmacol 1996;38:191-4.
81. Mizutani Y, Bonavida B. Pentoxifylline enhances sensitivity of a human ovarian cancer cell line (OVC-8) to TNF-alpha. Biotherapy 1993;7:109-14.
82. Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997;12:177-186.
83. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993;75:1169-78.
84. Suda T, Nagata S. Purification and characterization of the Fas-ligand that induces apoptosis. J Exp Med 1994;179:873-9.
85. Nagata S, Golstein P. The Fas death factor. Science 1995;267:1449-56.
86. Nagata S. Apoptosis: telling cells their time is up Curr Biol 1996;6:1241-3.
87. Nio Y, Zighelboim J, Berek J, Bonavida B. Cycloheximide-induced modulation of TNF-mediated cytotoxicity in sensitive and resistant ovarian tumor cells. Cancer Chemother Pharmacol 1990;26:1-8.
88. Mizutani Y, Bonavida B, Fukumoto M. Yoshida O. Enhanced susceptibility of c-myc anti sense oligonucleotide-treated human renal cell carcinoma cells to lysis by peripheral blood lymphocytes. J Immunother Emphasis Tumor Immunol 1995;17:78-87.
89. Safrit JT, Belldegrun A, Bonavida B. Sensitivity of human renal cell carcinoma lines to TNF, adriamycin, and combination: role of TNF mRNA induction in overcoming resistance. J Urol 1993;149:1202-8.
90. Morimoto H, Safrit JT, Bonavida B. Synergistic effect of tumor necrosis factor-alpha-and diphtheria toxin-mediated cytotoxicity in sensitive and resistant human ovarian tumor cell lines. J Immunol 1991;147:2609-16.
91. Wright SC, Jewett A, Mitsuyasu R, Bonavida B. Spontaneous cytotoxicity and tumor necrosis factor production by peripheral blood monocytes from AIDS patients. J Immunol 1988;141:99-104.
92. Frost PJ, Belldegrun A, Bonavida B. Sensitization of immunoresistant prostate carcinoma cell lines to Fas/Fas ligand-mediated killing by cytotoxic lymphocytes: Independence of de novo protein synthesis. Prostate 1999;41:20-30.
93. Beg AA, Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death [see comments]. Science 1996;274:782-4.
94. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-alpha-induced apoptosis by NF-kappaB [see comments]. Science 1996;274:787-9.
95. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC. A role for CD95 ligand in preventing graft rejection [see comments] [published erratum appears in Nature 1998 Jul 9; 394(6689): 133]. Nature 1995;377:630-2.
96. Moller P, Walczak H, Reidl S, Strater J, Krammer PH. Paneth cells express high levels of CD95 ligand transcripts: a unique property among gastrointestinal epithelia. Am J Pathol 1996;149:9-13.
97. Friesen C, Herr I, Krammer PH, Debatin KM. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 1996;2:574-7.
98. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini J, Tschopp J. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape [see comments]. Science 1996;274:1363-6.
99. Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH, Galle PR. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? [see comments]. Nat Med 1996;2:1361-6.
100. Friesen C, Fulda S, Debatin KM. Induction of CD95 ligand and apoptosis by doxorubicin is modulated by the redox state in chemosensitive- and drug-resistant tumor cells. Cell Death Differ 1999;6:471-480.
101. Muller M, Strand S, Hug H, Heinemann EM, Walczak H, Hofmann WJ, Stremmel W, Krammer PH, Galle PR. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO- 1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 1997;99:403-13.
102. Ferranni M, Imro MA, Sciorati C, Heltai S, Protti MP, Pellicciari C, Rovere P, Manfredi AA, Rugarli C. Blockade of the Fas-triggered intracellular signaling pathway in human melanomas is circumvented by cytotoxic lymphocytes. Int J Cancer 1999;81:573-9.
103. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors [see comments]. Science 1997;277:818-21.
104. Snell V, Clodi K, Zhao S, Goodwin R, Thomas EK, Morris SW, Kadin ME, Cabanillas F, Andreeff M, Younes A. Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br J Haematol 1997;99: 618-24.
105. Kothny-Wilkes G, Kulms D, Poppelmann B, Luger TA, Kubin M, Schwarz T. Interleukin-1 protects transformed keratinocytes from tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem 1998;273:29247-53.
106. Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 1999;11:255-60.
107. Zhang XD, Franco A, Myers K, Gray C, Nguyen T, Hersey P. Relation of TNF -related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma [In Process Citation]. Cancer Res 1999;59:2747-53.